Top Markets
#1 Akedo Akedo +73.50%
#2 MEET48 MEET48 +26.11%
#3 Bitway Bitway +21.76%
#4 VeThor VeThor +21.08%
#5 Power Protocol Power Protocol +17.38%
#6 Tutorial Tutorial +16.23%
#7 Astar Astar +14.86%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.72%
#9 Falcon Finance Falcon Finance +12.11%
#10 Arbitrum Arbitrum +12.09%
Coin of the day
Akedo Akedo
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Clasificación en acciones #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Precio por acción
$0.25974701
Última sincronización: 2025-01-06
Capitalización bursátil
$2.04M
Cambio (1 día)
0.74%
Cambio (1 año)
0.00%
País
FR
Comercio Acticor Biotech SAS (ALACT)

Categoría

Healthcare
Ratio P/B de Acticor Biotech SAS (ALACT)
Ratio P/B al September 2026 TTM: -0.57
Según los informes financieros más recientes y el precio de las acciones de Acticor Biotech SAS, el ratio P/B actual (TTM) es -0.57. Al final de 2022, el ratio P/B era -33.19.
Historial del ratio P/B de Acticor Biotech SAS desde 2010 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2026 (TTM) -0.57 -91.38%
2023 -6.59 -80.15%
2022 -33.19 -1,126.36%
2021 3.23 -87.62%
2020 26.12 538.96%
2019 4.09 17.85%
2018 3.47 -160.01%
2017 -5.78 -511.84%
2016 1.40 2.83%
2015 1.37 7.92%
2014 1.26 5.23%
2013 1.20 -8.34%
2012 1.31 -12.44%
2011 1.50 -91.22%
2010 17.05 0.00%
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5144 -1,247.10%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3983 -1,402.75%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9974 -803.89%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.5918 -1,612.91%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH